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Abstract In this retrospective observational study, we inves-
tigated the histopathological and demographic characteristics
of amyloid in gastrointestinal biopsies. From the Amyloid
Registry Kiel, we retrieved all cases with amyloid in biopsies
of the stomach, duodenum, small intestine, large intestine, and
rectum submitted for tertiary referral between January 2003
and April 2013. Amyloid was identified by Congo red stain-
ing in combination with polarization microscopy and classi-
fied by immunohistochemistry. The TTR-genotype was
assessed in 56 patients. Amyloid type was correlated with
demographic patient characteristics. Six hundred sixty-three
biopsies from 542 patients were retrieved. Amyloid was found
in each biopsy as vascular and/or interstitial amyloid deposits.
Biopsies were obtained from the colon [254 biopsies
(38.3 %)], stomach, [153 (23.1 %)], rectum [112 (16.9 %)],
duodenum [105 (15.8 %)], and jejunum/ileum [39 (5.9 %)].
ALλ amyloid was found in 286 (52.8 %), ATTR in 88
(16.2 %), ALκ in 74 (13.7 %), AA in 58 (10.7 %), and
ApoAI amyloid in 4 (0.7 %) patients. The remaining 21 cases
were ALys amyloid in 4 (0.7 %), AL n.o.s. in 14 (2.6 %), and
mixed type amyloidosis in 3 (0.6 %). The amyloid of 11
(2.0 %) cases remained unclassified. The median age of the
patients was 68 years. Men [332 (61.7 %)] were significantly
more prevalent than women [206 (38.3 %); p < 0.001]. TTR
mutations were found in 24 % of the patients with ATTR
amyloidosis. The median age, the histoanatomical distribution
(proximal to distal; mucosal to submucosal), and the deposi-
tion pattern (vascular/interstitial) varied between different am-
yloid types. Amyloid in gastrointestinal biopsies mainly af-
fects male elderly patients and shows amyloid-type-specific
demographic patient characteristics.
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Introduction
Amyloid is characterized by the pathological deposition of
peptides and proteins in diverse tissues and organs interfering
with normal tissue and organ function. It consists of
misfolded, insoluble, toxic peptide aggregates, which are ori-
ented in a β-sheet structure [1]. Up to now, 31 autologous,
physiological proteins have been identified, which can form
amyloid locally or systemically in diverse tissues and organs
[2]. The diagnosis is based on the histological examination of
an amyloid-containing specimen and the detection of a char-
acteristic green-yellow-orange birefringence under polarized
light after Congo red staining [3]. Nearly every organ or tissue
type can be affected, with the kidney, liver, heart, tongue,
autonomic nervous system, and gastrointestinal tract being
among the most common, clinically relevant, extracerebral
anatomical sites [3–5]. Renal amyloidosis can cause protein-
uria and renal failure [6–8]. Cardiac amyloidosis can lead to
arrhythmias, congestive heart failure, and patient death
[9–11]. Gastrointestinal amyloidosis can be associated with
abdominal pain, nausea, diarrhea, obstipation, and weight loss
[5, 12].
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Different types of amyloid may show different clinical pic-
tures. The most common type, i.e., immunoglobulin light
chain-derived (AL-) amyloidosis, can occur as local or sys-
temic variant and is able to involve almost every organ/tissue
type [13, 14]. However, renal and cardiac involvement is
found in more than 50 % of the patients [1]. Transthyretin-
derived (ATTR-) amyloidosis occurs as hereditary form due to
a point mutation in the TTR gene or as wildtype variant with-
out a germline mutation. Clinical presentation is characterized
by two main manifestations including senso-motoric
polyneuropathy and (restrictive) cardiomyopathy [15–17].
Amyloid A (AA-) amyloidosis mainly presents with renal
involvement [1]. Hereditary apolipoprotein AI-derived
(AApoAI-) is a systemic disease and frequently involves the
liver, kidney, larynx, skin, and myocardium [18]. Clinical pre-
sentation of hereditary lysozyme-derived (ALys-) amyloidosis
is variable and may present with renal manifestations, gastro-
intestinal symptoms, and bleeding events [19, 20].
Amyloidosis can be treated and therapy depends on early di-
agnosis and a correct classification [3].
Almost 60 years ago, rectal biopsy was introduced as a
diagnostic procedure for the detection of amyloid [21, 22].
Since then, our knowledge of the pathology of amyloid and
amyloidosis as well as diagnostic tools (e.g., flexible endos-
copy) used by gastroenterologists improved substantially and
it is well recognized that amyloid can affect diverse sites of the
gastrointestinal tract, leading to the conjecture that rectal bi-
opsy may not be the only location suitable for the detection of
amyloid. In addition, we have learnt that the diverse forms of
amyloid show unique patterns of organ manifestation.
In this retrospective observational study on the hitherto
largest series of amyloid- containing biopsies obtained from
the gastrointestinal tract, we tested the following hypotheses:
(1) the gastrointestinal tract is affected by diverse types of
amyloid, the different types of amyloid show (2) specific de-
mographic patient characteristics and (3) unique proximal-
distal (horizontal) andmucosal-submucosal (vertical) distribu-




From the Amyloid Registry Kiel, we retrieved all cases with
histologically proven amyloid in biopsy specimens of the
stomach, duodenum, small intestine, large intestine, and rec-
tum. Esophageal biopsies were not included, as only six biop-
sies were documented in the Amyloid Registry. A biopsy is
defined as a collection of biopsy fragments obtained from a
given site in a given patient at a given time point. All biopsy
specimens were obtained between January 2003 and April
2013 and referred to the Amyloid Registry for a second opin-
ion, i.e., confirmation of amyloid, and subsequent classifica-
tion of the amyloid type. Forty eight biopsies from 45 patients
submitted to the Amyloid Registry Kiel were excluded from
this series. The presence of amyloid could not be confirmed.
Clinical information was not available, as almost all referrals
were submitted by surgical pathologists after they had reached
a diagnosis of amyloid in the tissue specimens. This study was
performed according to the Declaration of Helsinki. Ethical
approval was obtained from the local ethical review board (D
581/15-585/15). All patient data were pseudonymized prior to
study inclusion. Written informed consent was not sought for
this retrospective observational study on archival tissue spec-
imens. Samples were anonymized pr ior to non-
individualizing TTR-gene testing.
Histology
All tissue biopsies had been fixed in formalin and embedded
in paraffin. At the Amyloid Registry, serial sections were cut
from each paraffin block and stained with hematoxylin and
eosin, Congo red, and for immunostaining (see below). The
presence of amyloid was confirmed when a typical green-
yellow-orange birefringence was found in cross-polarized
light in Congo red-stained sections. The anatomical distribu-
tion of amyloid was documented for every biopsy specimen
with regard to vascular and interstitial as well as mucosa,
muscularis mucosae, and submucosa.
Immunohistochemistry
The immunohistochemistry was carried out with commercial-
ly available monoclonal antibodies directed against AA amy-
loid (1:2000) and polyclonal antibodies directed against amy-
loid P-component (1:2000), fibrinogen (1:1000), lysozyme
(1:2000), prealbumin (1:3000), lambda-light chain (1:1:50,
000), and kappa-light chain (1:100,000; all DAKO,
Hamburg Germany) and non-commercially available poly-
clonal antibodies directed against apolipoprotein A1 (anti-
apo A1; dilution 1:1000), lambda-light chain-derived amyloid
proteins (AL1 antibody, 1:250), anti-lambda-light chain pep-
tide antibodies (AL3, 1:250; AL7, 1:200), transthyretin
(TTR3, 1:2000), and kappa-light chain amyloid proteins
(AK3, 1:1000). Immunostaining was done on formalin-fixed
and paraffin-embedded sections with the BenchMark®XT
immunostainer using the ultraView™ Universal Alkaline
Phosphatase Red (in older cases brown) Detection Kit (both
from VentanaMedical Systems, Inc. Tucson, Arizona) or with
the Bond Max Leica immunostainer using the Bond Polymer
Refine Red Detection Kit (Leica Microsystems, Wetzlar,
Germany). Antigen retrieval was carried out with ER2-Bond
Epitope Retrieval Solution 2 (amyloid P-component, lambda-
light chain, kappa-light chain, TTR3, and prealbumin), ER1-
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Bond Epitope Retrieval Solution 1 (apo A1 and fibrinogen),
or Enzyme 1 (AL7; all Leica Microsystems, Germany) ac-
c o r d i n g t o t h e m a n u f a c t u r e r ’s i n s t r u c t i o n s .
Immunohistochemical classification was carried out and had
been validated as described in detail elsewhere [23–27]. In
brief, identification of the amyloid was considered to be pos-
itive when there was a strong and homogenous immunostain-
ing of the entire amyloid deposits. Uneven and weak staining
of some deposits was not assumed to be proof of the amyloid
protein. If the staining was clearly positive with more than one
antibody against different amyloid precursor proteins, the case
was categorized as mixed amyloidosis. AL amyloid not oth-
erwise specified (n.o.s.) were characterized by staining with
antibodies directed against λ- and κ-light chain.
Immunostaining with antibodies directed against fibrino-
gen and lysozyme were done routinely until 2011.
Subsequently, immunostaining was done with these antibod-
ies only when AFib- or ALys-amyloidosis was within the
differential diagnosis. The anti-prealbumin antibody was re-
placed in 2010 by the anti-TTR peptide antibody (TTR3). The
anti-lambda light chain antibody AL7was introduced in 2007,
while the antibody directed against AL3 was used until 2011.
The anti-kappa-light chain antibody AK3 was routinely used
since 2011. On slide positive and negative controls using a
tissuemicroarraywith AA-, ALλ-, and ATTR-amyloid as well
as non-neoplastic liver tissue were used on each staining
round.
Assessment of TTR-genotype
The TTR-genotype (exons 1 through 4) was assessed as de-
scribed in detail previously using formalin-fixed and paraffin-
embedded tissue samples. The numbering of amino acid res-
idues refers to the mature TTR protein following the guide-
lines of the International Society of Amyloidosis [2].
Statistics
Analyses and statistical tests were carried out with IBM SPSS
Statistics Version 20. Significances of correspondence be-
tween variables in cross tables were determined using
Fisher’s exact test. Significances of differences between age
distributions of the amyloidosis types were tested using
Kruskal-Wallis test (overall differences) and Mann-Whitney
U test (pairwise differences). Chi-square test for equal distri-
bution was used to test distributions of localization for the
distinct amyloidosis types. Significance of differences be-
tween proportions was tested using the “2-sample test for
equality of proportions with continuity correction” from R
Version 3.2.0. All p-values are given unadjusted. A p ≤ 0.05
was considered statistically significant. Effects of multiple
testing were accounted for by group-wise application of the
Simes (Benjamini-Hochberg) procedure for control of false
discovery rate [28].
Results
Six hundred sixty-three biopsies from 542 patients were avail-
able with amyloid. AL amyloid of lambda light chain origin
(ALλ) was found in 286 (52.8 %), ATTR amyloid in 88
(16.2 %), AL amyloid of kappa-light chain origin (ALκ) in
74 (13.7 %), and AA amyloid in 58 (10.7 %) cases. ApoAI
amyloid was an uncommon diagnosis in biopsies of the gas-
trointestinal tract [4 (0.7 %) cases] as well as ALys amyloid [4
(0.7 %)]. In 14 (2.6 %) patients with AL amyloidosis, the
subclassification of amyloid was impossible and the cases
were categorized as AL n.o.s. amyloidosis. Mixed amyloid
showing clearly positive staining with more than one antibody
against different amyloid precursor proteins was found in bi-
opsies obtained from 3 (0.6 %) patients, i.e., AA- and ATTR-
amyloid, ALλ- and ATTR-amyloid, and ALκ- and ATTR
each in a single colon or rectal biopsy. In 11 (2.0 %) cases,
the amyloid deposits remained unclassified.
Biopsies from two different anatomical regions were avail-
able from 86 patients, three from 16 patients and four from a
single patient. In all cases with biopsies obtained from differ-
ent anatomical regions of the gastrointestinal tract, the amy-
loid type classified by immunohistochemistry was identical.
Patient demographics
First, we correlated the distribution of the different types of
amyloid with patient age and gender.
The overall median age at diagnosis was 68.0 years (range
17 to 100 years; Table 1). In five patients, the age was un-
known. The highest median age was found in ATTR amyloid-
osis (73.0 years), followed by ALκ- (68.0 years), ALλ-
(66.0 years), and AA amyloidosis (64.0 years). Cases with
unclassified amyloid deposits had the lowest median age
(61.0 years). Testing the distribution of all medians together
for randomization, a p value <0.001 was calculated, indicating
that the median age distribution of the different types of am-
yloidosis is not random. Subsequently, we compared the am-
yloid types directly. The difference in median age was found
to be significant between ALλ- and ATTR amyloidosis and
between AA- and ATTR amyloidosis (p < 0.001; respective-
ly). Interestingly, no statistical difference was found between
unclassified amyloidosis (61.0 years) and ALλ- or ALκ
amyloidosis.
In general, amyloid in the gastrointestinal tract seems to be
a finding in the elderly, since over 70 % of the patients were
≥60 years of age (Table 1). The majority (67 %) of patients
with ATTR amyloidosis were even >70 years old. An excep-
tion to this rule was found in AA amyloidosis. Thirty seven
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percent of the patients with AA amyloidosis were younger
than 61 years.
Three hundred thirty-two (61.7 %) patients were male and
206 (38.3 %) female. In four (0.7 %) cases, the gender was
unknown (Table 1). The gender difference was significant
(p < 0.001) irrespective of the amyloid type. However, few
non-significant variations were noticed in gender ratio. In
ALλ, the ratio (men vs. women) was 65.0 vs. 35.0 % and in
ALκ 52.7 vs. 47.3 %. In four patients with AApoAI amyloid,
the gender ratio was even, and in 11 patients with unclassified
amyloid, the ratio was 81.8 vs. 18.2 %
Histoanatomical distribution of amyloid
Next, we assessed the distribution pattern of the different types
of amyloid from proximal to distal (“horizontal”) and from the
lamina propria to the submucosa (“vertical”).
Anatomical distribution from proximal to distal
(“horizontal”)
Most biopsies were obtained from the colon [254 biopsies
(38.3 %)], followed by the stomach, [153 (23.1 %)], rectum
[112 (16.9 %)], duodenum [105 (15.8 %)], and jejunum/ileum
[=small intestine; 39 (5.9 %)]. With regard to total numbers,
each type of amyloid was found most commonly in colon
biopsies, except for ALκ amyloidosis, which was found more
often in stomach biopsies [stomach 29 (31.2 %); colon 26
(28.0 %)] and also unclassified amyloidosis [stomach 5
(33.3 %); colon 3 (20.0 %)]. Since total numbers might be
biased by preferred sampling sites, we next analyzed the pro-
portional distribution of the different amyloid types (Fig. 1).
This showed that ALλ amyloidosis was the most common
amyloid type in every anatomical region of the gastrointestinal
tract (on average 52.3 %). Interestingly, its proportional
prevalence steadily increased from 49.7 % in the stomach to
56.2 % in the rectum (Fig. 1). The second most common type
was ATTR amyloid (on average 15.7 %), showing a similar
increase in its proportional prevalence from stomach (9.8 %)
to rectal biopsy sites (20.5 %; Fig. 1). An inverse proportional
prevalence was found for ALκ- and AA amyloidosis (Fig. 1).
ALκ- and AA amyloidosis were found most commonly in
stomach and duodenal biopsies. Unclassified amyloidoses
were most prevalent in biopsies of the small intestine.
The “horizontal” proportional distribution of the different
amyloid types was statistically significant with regard to the
entire group (p = 0.003) as well as with regard to ALκ-
(p = 0.001) and ATTR amyloidosis (p = 0.006). However,
the uneven horizontal distribution of ALλ- (p = 0.805) and
AA amyloidosis (p = 0.849) was insignificant. The number of
biopsies with other types of amyloid and unclassifiable amy-
loid were too small for statistical analyses.
Anatomical distribution from the lamina propria
to the submucosa (“vertical”)
Next, we analyzed the proportional distribution of the differ-
ent amyloid types vertically, i.e., proportional distribution of
the different amyloid types in the lamina propria, muscularis
mucosae, and submucosa irrespective of the horizontal distri-
bution (Fig. 2; Suppl. Table 1).
Six hundred sixty (99.5 %) of 663 biopsies included lamina
propria, amyloid was found in 477 (72.3 %) biopsies.
Involvement of the lamina propria was most prevalent in the
stomach [132 biopsies (86.3 %)] followed by duodenum [79
(75.2 %)], jejunum/ileum [=small intestine; 25 (64.1 %)], co-
lon [170 (67.2 %)], and rectum [71 (64.5 %)]. The differences
between stomach and duodenum (p = 0.032), as well as stom-
ach and colon (p < 0.001), were statistically significant.
However, after correction for multiple testing, the difference
Table 1 Correlation of amyloid types with patient age and gender
Amyloid-
type







<31 31–40 41–50 51–60 61–70 71–80 81–90 >90 Total Male Female
AL lambda 283 (52.7) 66.0 25–100 1 (0.4) 2 (0.7) 23 (8.1) 52 (18.4) 97 (34.3) 95 (33.6) 12 (4.2) 1 (0.4) 283 (52.6) 184 (65.0) 99 (35.0)
AL kappa 74 (13.8) 68.0 45–93 0 (0.0) 0 (0.0) 4 (5.4) 13 (17.6) 22 (29.7) 28 (37.8) 6 (8.1) 1 (1.4) 74 (13.8) 39 (52.7) 35 (47.3)
AL n.o.s. 13 (2.4) 69.0 40–86 0 (0.0) 1 (7.7) 0 (0.0) 1 (7.7) 5 (38.5) 3 (23.1) 3 (23.1) 0 (0.0) 14 (2.6) 9 (64.3) 5 (35.7)
ATTR 88 (16.4) 73.0 40–92 0 (0.0) 0 (0.0) 5 (5.7) 12 (13.6) 12 (13.6) 37 (42.0) 21 (23.9) 1 (1.1) 88 (16.4) 53 (60.2) 35 (39.8)
AA 57 (10.6) 64.0 32–86 0 (0.0) 5 (8.8) 3 (5.3) 13 (22.8) 18 (31.6) 14 (24.6) 4 (7.0) 0 (0.0) 57 (10.6) 33 (57.9) 24 (42.1)
AApoAI 4 (0.7) 67.5 62–75 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0) 4 (0.7) 2 (50.0) 2 (50.0)
ALys 4 (0.7) 41.5 17–65 1 (25.0) 1 (25.0) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.7) 2 (50.0) 2 (50.0)
Mixed 3 (0.6) 72.0 71–72 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 0 (0.0) 0 (0.0) 3 (0.6) 1 (33.3) 2 (66.7)
unclassified 11 (2.0) 61.0 44–87 0 (0.0) 0 (0.0) 3 (27.3) 1 (9.1) 3 (27.3) 2 (18.2) 2 (18.2) 0 (0.0) 11 (2.0) 9 (81.8) 2 (18.2)
Total 537a (100.0) 68.0 17–100 2 (0.4) 8 (1.5) 40 (7.4) 92 (17.1) 161 (30.0) 183 (34.1) 48 (8.9) 3 (0.6) 538b (100.0) 332 (61.7) 206 (38.3)
a In 5 patients, the age was not known
b In 4 patients, the gender was not known
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between stomach and duodenum lost significance (adjusted p
limit <0.031). Amyloid deposits in the lamina propria were
found more commonly in the interstitium [472 (99 %)
biopsies] and less commonly in vessel walls [314 (65.8 %)].
Interstitial deposits only were found in 163 (34.2 %) biopsies,
a mixed interstitial/vascular deposition pattern in 309 (64.8 %)
AL lambda ATTR AL kappa AA other unclassified
Stomach 49.7% 9.8% 18.3% 12.4% 5.9% 3.9%
Duodenum 49.5% 9.5% 21.9% 11.4% 2.9% 4.8%
Jejunum/Ileum 51.3% 10.3% 7.7% 10.3% 10.3% 10.3%
Colon 53.1% 20.1% 9.1% 10.6% 3.9% 3.2%








Fig. 1 Proportional prevalences of different amyloid types in gastrointestinal biopsies: anatomical distribution from proximal to distal
AL lambda ATTR AL kappa AA
Lamina propria interstitial 79% 14% 89% 89%
Lamina propria vascular 49% 09% 68% 69%
Muscularis mucosae interstitial 96% 39% 98% 90%
Muscularis mucosae vascular 67% 59% 79% 83%
Submucosa interstitial 97% 48% 99% 74%












Fig. 2 Proportional prevalences of different amyloid types in gastrointestinal biopsies: anatomical distribution from mucosal to submucosal
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biopsies, and vascular involvement only in 5 (1 %; p < 0.001).
Irrespective of the amyloid type, amyloidosis of the lamina
propria was most prevalent in the stomach compared with
more aborally located biopsy sites
Among the different types, involvement of the lamina
propria was most prevalent in AA amyloidosis [64
(90.1 %)], followed by ALκ- [83 (89.2 %)] and ALλ amyloid-
osis [273 (79.4 %)]. Involvement was least common in ATTR
amyloidosis [16 (15.4 %)] (Fig. 2). The differences between
ALλ- and AA amyloidosis did not reach significance after
multiple testing (p = 0.044; adjusted p limit <0.035).
However, the difference between ALλ- and ATTR amyloid-
osis was statistically significant (p < 0.001). In addition to the
differences in the proportional distribution of the different
amyloid types, we also noted differences in the general histo-
logical appearance of the amyloid types. In ALλ amyloidosis,
involvement of the lamina propria often exhibited small am-
yloid deposits located in form of a rim under the surface epi-
thelium, while in AA- and ALκ amyloidosis, the amyloid
deposits were often gross/patchy and located in the entire mu-
cosa (Fig. 3).
Six hundred fifty-five (98.8 %) of 663 biopsies included
muscularis mucosae (Suppl. Table 1). Most of the cases
showed amyloid deposits in the interstitium (Fig. 2). The
muscularis mucosae was involved in >90 % of the biopsies
with ALλ-, ALκ-, or AA amyloidosis (Suppl. Table 1).
Vascular amyloid deposits were present in 232 (67.4 %) cases
with ALλ amyloidosis, followed by ALκ- [72 (79.1 %)] and
AA amyloidosis [58 (82.9 %)]. The difference between ALλ-
and AA amyloidosis was significant (p = 0.01). In ATTR
amyloidosis vascular amyloid deposits of the muscularis mu-
cosae were more prevalent [61 biopsies (59.2 %)] compared
with interstitial deposits [40 (38.8 %)]. The difference of in-
terstitial amyloid was significant between ALλ- and ATTR
amyloidosis (p < 0.001)
649 biopsies enclosed submucosa (Suppl. Table 1).
Submucosal vessels were enclosed in 648 biopsies. Every
biopsy showed amyloid in the submucosa. Vascular amyloid
deposits were found in >90 % of the biopsies. However, dif-
ferences were found in the proportional distribution among
different amyloid types. Interstitial amyloid deposits were
found only in 49 biopsies (48.0 %) with ATTR amyloid.
Interstitial amyloid deposits were more prevalent in AA- [52
(74.3 %)], ALλ- [333 (97.4 %)], and ALκ amyloidosis [88
(98.9 %)](Fig. 2). The differences between ALλ- and AA- or
ATTR- amyloidosis, as well as between ALκ- and AA amy-
loidosis, and between ATTR- and AA amyloidosis were sig-
nificant (p ≤ 0.001; respectively).
TTR-genotype
In 56 patients with ATTR amyloidosis, formalin-fixed and
paraffin-embedded tissue samples were available for molecu-
lar testing. In 18 patients, the quality of the DNA extracted
was insufficient, and 38 patients remained, in whom all four
exons of the TTR-gene could be analyzed. Twenty-nine pa-
tients (76.3 %) showed a wild-type sequence and were classi-
fied as senile cardiovascular ATTR amyloidosis. Nine
(23.7 %) patients carried a mutation and were classified as
hereditary ATTR amyloidosis. Patients with hereditary
ATTR amyloidosis were significantly younger [median age
70 years; range 43–75 years] compared with those suffering
from senile cardiovascular ATTR amyloidosis [median age
77 years; range 42–92 years; p = 0.021]. Of nine patients
carrying a mutation, 6 were male and 3 female.
Unclassified Amyloidoses
In the 15 biopsies of 11 patients, the amyloid deposits
remained unclassified. The amyloid type of two patients (three
biopsies) could not be defined because of technical reasons,
i.e., missing serial sections for immunostaining. In the remain-
ing 12 biopsies of 9 patients, the amyloid deposits did not stain
with any of our antibodies.
Discussion
Annually, the Amyloid Registry Kiel receives on average 110
referrals for the classification of amyloid in gastrointestinal
biopsy specimens. These represent 21 % of all registry cases
Fig. 3 Comparison of the deposition pattern of four with different types
of amyloid. AA-amyloid in a stomach biopsy (a), ALλ amyloid in a
stomach biopsy (b), ALκ amyloid in a colon biopsy (c), and ATTR
amyloikd in a rectal biopsy (d). Immunostaining with antibodies
directed against AA amyloid (a), λ-light chain (b), κ-light chain (c),
and transthyretin (d). Original magnifications threefold
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and are the most common biopsy site, followed by the heart
(18 %) [4] and carpal tunnel ligament (8 %) [23]. The unique
centralized service offers the chance to collect large patient
series and testing histopathological and demographic charac-
teristics of the diverse types of amyloid. This may improve
daily practice in clinics as well as in diagnostic surgical pa-
thology of an otherwise rare disease. Our retrospective obser-
vational study on the hitherto largest series of amyloid-bearing
gastrointestinal biopsies shows that the gastrointestinal tract is
affected by diverse types of amyloid and at different anatom-
ical sites. Any amyloid-containing biopsy of any anatomical
site of the gastrointestinal tract is suitable to reach a proper
diagnosis and to classify amyloid. However, the different
types of amyloid vary with regard to age, gender, vascular-
interstitial, proximal-distal (horizontal), and mucosal-
submucosal (vertical) distribution patterns. This knowledge
may be used to guide biopsy procedures and support classifi-
cation of amyloid and is therefore of immediate diagnostic
value. Previously, it was shown that cardiac biopsies frequent-
ly enclose either ALλ- or ATTR amyloid, while liver biopsies
comprise a high proportion of ALκ amyloid [4, 29]. These
observational findings are now extended to biopsies of the
gastrointestinal tract. While ALλ amyloidosis is the most
common type in gastrointestinal biopsies, its proportional
prevalence increases from proximal to distal, as it also does
for ATTR amyloidosis. ALκ amyloidosis shows the opposite
relationship. Similarly, the “vertical” (mucosal to submucosal)
and vascular/interstitial distribution pattern of the different
types of amyloid varies (Fig. 2). Mucosal involvement was
common in AA- and ALκ amyloidosis, less frequently in ALλ
amyloidosis, and very rare in ATTR amyloidosis. These ob-
servations confirm findings made by Said et al. [12]. In their
series of 79 cases with gastric amyloidosis, involvement of the
lamina propria was observed less frequently in ATTR amy-
loidosis compared with other types. Mucosal involvement in
AA- and less frequently in AL amyloidosis was also reported
by others [30–32]. Alcarde-Vargas et al. [33] described differ-
ences in the histoanatomical distribution of amyloid between
submucosa and lamina propria, which correlated with the en-
doscopic findings but not with the amyloid type. However,
Alcarde-Vargas et al. [33] studied only 24 patients with three
different types of amyloid. We found commonly AA-, ALλ-,
and ALκ amyloid in the muscularis mucosae (each ≥90 % of
the biopsies). Again, interstitial ATTR amyloidosis occurred
significantly less frequently in the muscularis mucosae
(<40 %), but vascular involvement was encountered more
frequently (approx. 60 %). Said et al. [12] and Gilat et al.
[34] reported similar findings in AL amyloidosis, while
Röcken et al. [26] previously reported lower prevalences
(37 %). However, our previous investigation did not cor-
relate the amyloid type with the histoanatomical distribu-
tion and enclosed a much lower number of cases with AL
amyloidosis [26].
Kyle et al. [22] already reported 50 years ago that tissue
sampling influences the sensitivity of amyloid detection being
higher when submucosal layers are enclosed. Gastrointestinal
biopsies from patients suffering from amyloidosis, which do
not contain submucosa, may miss the deposits in more than
60 % [26]. As shown here, the problem of a sampling error is
most evident in ATTR amyloidosis. Compared with all other
types, mucosal involvement was least common in ATTR am-
yloidosis (Suppl. Table 1). Submucosal involvement, mostly
of vessel walls, was found in every biopsy and has also been
reported previously [32, 34, 35]. Thus, ATTR amyloidosis
carries the highest risk of a sampling error, when submucosal
layers are not enclosed in the biopsy specimen.
Along the proximal-distal axis of the gastrointestinal tract,
the anatomical site may also impact on the mucosa/
submucosal and vascular/interstitial deposition pattern. Gilat
et al. [34] found mucosal involvement of the stomach and
duodenum more frequently than in the colon in their series
of 68 patients, with only 16 suffering from AL amyloidosis.
Yamada et al. [32] reported a higher prevalence of mucosal
involvement in AL amyloidosis of the stomach compared
with colon on their series of 21 autopsy cases (18 AL- and 3
AA amyloidoses). However, no difference was found for AA
amyloidosis. Similarly, in our series, the difference between
stomach and colon mucosa was less prominent for AA amy-
loidosis compared with ALλ amyloidosis. The organ site-
specific differences in the deposition pattern of AL amyloid-
osis prompted Yamada et al. [32] to recommend stomach bi-
opsies as preferable anatomical site for biopsy confirmation of
AL amyloidosis: mucosal involvement is much more preva-
lent in gastric biopsies and limits the risk of sampling bias,
when submucosal layers are missed by the biopsy procedure.
We would extend this recommendation in stating that ALκ-
and AA amyloidosis should be sought in biopsies of the upper
gastrointestinal tract, while ALλ- and ATTR amyloidosis
should be sought preferentially in colorectal biopsies
enclosing submucosal layers.
In Western countries, AL amyloidosis is the most common
variant of systemic amyloidosis [1, 5]. As shown here and
previously by others, this also applies to the gastrointestinal
tract [12, 32, 36, 37], with ALλ being more prevalent than
ALκ [12, 32]. However, hereditary amyloidosis may also af-
fect the gastrointestinal tract. We found cases with AApoAI-
and ALys amyloidosis. Thus, special care should be taken not
to miss hereditary amyloidosis in biopsies of the gastrointes-
tinal tract [38]. Hereditary ATTR amyloidosis is the most
prevalent type in Germany, with many patients suffering from
gastrointestinal symptoms, some of which may be related to
visceral polyneuropathy [39, 40]. Separation of hereditary
from wild-type ATTR amyloidosis has clinical implications
with regard to therapy and further genetic counseling [41].
In the literature, the prevalence ranges from 24 to 85 % [4,
12, 36, 42]. The differences in the prevalence might be related
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to patient selection and origin of the biopsy specimen. Higher
prevalences are to be expected in endemic regions of heredi-
tary ATTR amyloidosis such as Portugal, Sweden, and Japan
[43–48]. Collectively, these data show that hereditary ATTR
amyloidosis is sampled by gastrointestinal biopsies and that
the median age of these patients (70 years) is in the range of
AA- and AL amyloidosis. Additionally, we recommend that
genetic counseling should be offered to every patient with
ATTR amyloidosis in gastrointestinal biopsies, since patient
age shows a considerable overlap between senile systemic and
hereditary ATTR amyloidosis and is of little help to distin-
guish both types.
In summary, amyloid in gastrointestinal biopsies is found
preferentially in elderly male patients and is most commonly
of AL type. The different types of amyloid show distinctive
deposition patterns, which may help to improve diagnostic
procedures, i.e. choice of endoscopic biopsy site, and tissue-
based classification of amyloid. Based on our findings, we
propose that if systemic amyloidosis is suspected clinically,
ALκ- and AA amyloidosis should be sought preferentially in
biopsies of the upper gastrointestinal tract and ALλ- and
ATTR amyloidosis in biopsies of the large intestine enclosing
submucosal layers.
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